Let's Build Better Cells Together

Navigate your way from concept to clinic by partnering with MaxCyte®.

We've spent over 20 years perfecting the art of cell engineering and venturing beyond today's process to innovate tomorrow's solutions. Our ExPERT™ instruments feature best-in-class electroporation technology combining high efficiency and cell viability with seamless scalability, all backed by a global team of technical and regulatory experts providing ongoing support.

We provide the spark of collaboration empowering research into treatments and cures that will transform human health. Chart your best course with MaxCyte.

We are thrilled to support CRISPR Therapeutics and Vertex Pharmaceuticals in celebrating the approval of their MaxCyte-enabled groundbreaking CRISPR/Cas9 gene-edited cell therapy, exa-cel™ for the treatment of sickle cell disease. Learn More...

Research Applications

Cell Therapy

Discover scalable engineering to enable safe and potent cell therapies.

Cell Based Assays

Produce assay-ready cells faster with scalable electroporation.

Antibody & Protein Production

Accelerate biotherapeutic development with transient expression for gram-scale protein production.

Viral Vector Production

Transfect adherent or suspension cells to produce a variety of viral vectors.

Gene Editing

Navigate the complexities of genome engineering with highly efficient delivery.


Innovate vaccine research with our adaptable platform for production of recombinant proteins, virus-like particles and more.

Explore the research we've supported

See how MaxCyte technology is advancing our partners' biomedical innovations

Application Note
Triple-Engineered NYCE cells as T Cell Therapy for Refractory Cancers
Clinical Scale Delivery of nS/MARt Vectors for CAR T Cell Engineering
Application Note
Highly Efficient CAR T Cell Engineering, with CRISPR and Single-Stranded Cas9 Target Sequences.

We're here throughout your journey

Because bringing a new therapeutic to market is a long and complex endeavor, we offer our expertise to support your innovations and chart a more direct course to success.

The benefits of our collaborative approach can be seen in over 35 clinical trials. Our technology has enabled studies by leaders in pharmaceutical and biotechnology research developing treatments for a variety of indications including cancer, heart disease, central nervous system disorders and rare genetic diseases.


Show More


Scientific Briefs
Scientific Posters
App Notes

MaxCyte News

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology


Mar 08, 2023

Latest News